Blog Posts Across nodrama

InterMune Announces Progress on Pirfenidone in IPF * Initiating planned roll-over study for CAPACITY patients in Q3 * Patient retention and conduct of Phase 3 CAPACITY program remain excellent to date * Abstract of Shionogi Phase 3 pirfenidone study now available on ATS website BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will initiate an open-label roll-over study to evaluate the long-term safety of pirfenidone in patients with id… Continue